Ad5/3-hTERT-E1A-hCD40L
AXP000070.1 · Oncolytic virus
- Platform
- adenovirus (Ad5/3 chimera, hTERT promoter, CD40L-armed)
- Originator
- University of Helsinki (Akseli Hemminki)
Names
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5/3 chimera
- Replication
- conditionally replicating
- Modifications
- hTERT promoter drives E1A; Ad3 fiber knob
- Transgenes
- CD40LG
- Route
- intratumoral, intraperitoneal, intrapleural, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 22396493 | Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. | Cancer research | 2012 | name in abstract: Ad5/3-hTERT-E1A-hCD40L |
Notes
ATAP construct (2007-2012), written Ad5/3-hTERT-CD40L in some reports and reported elsewhere under the code CGTG-401; the code was not verified here.
How to cite
Ad5/3-hTERT-E1A-hCD40L (AXP000070.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000070.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.